"We know for sure that the vaccine can be used by all people aged over 18, we will now go down [proceed to vaccination of younger citizens]. We understand that vaccine injection results in the development of effective antibodies in 94 percent of cases," Alexander Semyonov told the Soloviev Live YouTube show.
Russian consumer rights watchdog Rospotrebnadzor specified later that Semyonov was talking about antibodies in people aged 60+.
EpiVacCorona vaccine was authorised for seniors aged 60 and over in March.
The vaccine is a peptide-based drug that relies on a synthetic platform. Artificially-synthesised short fragments of viral proteins - peptides, which are contained in the vaccine, help the immune system learn how to recognise and then neutralise the virus.